Li Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Li has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Chengping Hu
Department of Respiratory Medicine (Department of Respiratory and Critical Care Medicine), Xiangya Hospital, Central South University, Changsha, People’s Republic of China
1 shared publication - Chengyuan Tang
Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha 410011, China
1 shared publication - Chenrui Li
Department of Nephrology, The Second Xiangya Hospital Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, No. 139 Renmin Middle Road, Changsha, Hunan,China
1 shared publication - Dongjing Cai
Cent South Univ, Xiangya Hosp, Dept Neurol, Hunan Key Lab Mol Precis Med, Changsha 410008, Peoples R China
1 shared publication - Fuyou Liu
Department of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, The Second Xiangya Hospital, Central South University, Changsha, China
1 shared publication Han Han‐Zhang
Burning Rock Biotech, Guangzhou International Biotech Island, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5781
Abstract 5781: Molecular positive margin of surgical resections is a strong biomarker for tumor recurrence in pIIIA-N2 NSCLC patients
Background: The high recurrence rate of stage pIIIA-N2 NSCLC patients may reflect inadequate removal of all residual tumor cells despite conventional histologic negative surgery margin. The NGS-detected BRM status was possible to serve as a more accurate examination to identify those patients with a high-risk of postoperative recurrence. Methods: We retrospectively studied 119 stage IIIA-N2 NSCLC patients who received curative-intent surgery plus adjuvant chemotherapy/chemoradiotherapy, and all of the patients were classified with negative resection margin by the conventional histologic method. Each patient had paired tumor and bronchial resection margin (BRM) samples, which were analyzed using next-generation sequencing (NGS) of 474 cancer-related genes, and we explored the prognostic values of various clinical and molecular features. Results: Among the 119 stage IIIA-N2 NSCLC patients with histologic negative resection margins, the BRM samples from 56 patients (47.1%) were positive for tumor mutations, including multiple lung cancer driver mutations. The number and the variant allele frequency of genetic alterations in BRM samples were generally lower than that of the paired tumor samples. Notably, patients who were positive for NGS-detected BRM mutations had significantly shorter disease-free survival (DFS) than the negative patients (p=0.001, HR 2.18, 95%CI 1.37~3.47). Several other clinical/molecular features were also found to be significantly associated with DFS, including the metastatic lymph node ratio (MLNR), smoking history, and KRAS mutation status, and NGS-assessed BRM status remained to be statistically significant in multivariable analysis by including all of these prognostic factors (p =0.020, HR 1.82, 95%CI 1.10~3.02). Conclusions: We demonstrated that the molecular positive margin of surgical resections was a strong and independent biomarker for disease recurrence in pIIIA-N2 NSCLC patients. Our results emphasized the clinical utility of molecular diagnostic approaches to detect minimal residual disease after surgical resection, which could potentially facilitate the stratification of high-risk patients for personalized and appropriate treatments. Citation Format: Li Li, Kewen He, Jiaohui Pang, Yang Xu, Yang Shao, Shuanghu Yuan, Jinming Yu. Molecular positive margin of surgical resections is a strong biomarker for tumor recurrence in pIIIA-N2 NSCLC patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5781.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5781
Open AccessAbstract 5781: Molecular positive margin of surgical resections is a strong biomarker for tumor recurrence in pIIIA-N2 NSCLC patients
Background: The high recurrence rate of stage pIIIA-N2 NSCLC patients may reflect inadequate removal of all residual tumor cells despite conventional histologic negative surgery margin. The NGS-detected BRM status was possible to serve as a more accurate examination to identify those patients with a high-risk of postoperative recurrence. Methods: We retrospectively studied 119 stage IIIA-N2 NSCLC patients who received curative-intent surgery plus adjuvant chemotherapy/chemoradiotherapy, and all of the patients were classified with negative resection margin by the conventional histologic method. Each patient had paired tumor and bronchial resection margin (BRM) samples, which were analyzed using next-generation sequencing (NGS) of 474 cancer-related genes, and we explored the prognostic values of various clinical and molecular features. Results: Among the 119 stage IIIA-N2 NSCLC patients with histologic negative resection margins, the BRM samples from 56 patients (47.1%) were positive for tumor mutations, including multiple lung cancer driver mutations. The number and the variant allele frequency of genetic alterations in BRM samples were generally lower than that of the paired tumor samples. Notably, patients who were positive for NGS-detected BRM mutations had significantly shorter disease-free survival (DFS) than the negative patients (p=0.001, HR 2.18, 95%CI 1.37~3.47). Several other clinical/molecular features were also found to be significantly associated with DFS, including the metastatic lymph node ratio (MLNR), smoking history, and KRAS mutation status, and NGS-assessed BRM status remained to be statistically significant in multivariable analysis by including all of these prognostic factors (p =0.020, HR 1.82, 95%CI 1.10~3.02). Conclusions: We demonstrated that the molecular positive margin of surgical resections was a strong and independent biomarker for disease recurrence in pIIIA-N2 NSCLC patients. Our results emphasized the clinical utility of molecular diagnostic approaches to detect minimal residual disease after surgical resection, which could potentially facilitate the stratification of high-risk patients for personalized and appropriate treatments. Citation Format: Li Li, Kewen He, Jiaohui Pang, Yang Xu, Yang Shao, Shuanghu Yuan, Jinming Yu. Molecular positive margin of surgical resections is a strong biomarker for tumor recurrence in pIIIA-N2 NSCLC patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5781.
- Open Access
- 24 July 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 12599-12614
Aristolochic acid induces renal fibrosis by arresting proximal tubular cells in G2/M phase mediated by HIF‐1α
Renal tubulointerstitial fibrosis (TIF) is a common pathological feature of aristolochic acid (AA) nephropathy (AAN). G2/M arrest of proximal tubular cells (PTCs) is implicated in renal fibrosis of AAN, but the upstream regulatory molecule remains unknown. Hypoxia inducible factor‐1α (HIF‐1α) promotes renal fibrosis in kidney disease, but the role of HIF‐1α in AAN is unclear. Evidence shows that HIF‐1α and p21, a known inducer of cellular G2/M arrest, are closely related to each other. To investigate the role of HIF‐1α in renal fibrosis of AAN and its effects on p21 expression and PTCs G2/M arrest, mice with HIF‐1α gene knockout PTCs (PT‐HIF‐1α‐KO) were generated, and AAN was induced by AA. In vitro tests were conducted on the human PTCs line HK‐2 and primary mouse PTCs. HIF‐1α and p21 expression, fibrogenesis, and G2/M arrest of PTCs were determined. Results showed that HIF‐1α was upregulated in the kidneys of wild‐type (WT) AAN mice, accompanied by p21 upregulation, PTCs G2/M arrest and renal fibrosis, and these alterations were reversed in PT‐HIF‐1α‐KO AAN mice. Similar results were observed in HK‐2 cells and were further confirmed in primary PTCs from PT‐HIF‐1α‐KO and WT mice. Inhibiting p21 in HK‐2 cells and primary PTCs did not change the expression of HIF‐1α, but G2/M arrest and fibrogenesis were reduced. These data indicate that HIF‐1α plays a key role in renal fibrosis in AAN by inducing PTCs G2/M arrest modulated through p21. HIF‐1α may serve as a potential therapeutic target for AAN.
- 24 July 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 12599-12614
Open AccessAristolochic acid induces renal fibrosis by arresting proximal tubular cells in G2/M phase mediated by HIF‐1α
Renal tubulointerstitial fibrosis (TIF) is a common pathological feature of aristolochic acid (AA) nephropathy (AAN). G2/M arrest of proximal tubular cells (PTCs) is implicated in renal fibrosis of AAN, but the upstream regulatory molecule remains unknown. Hypoxia inducible factor‐1α (HIF‐1α) promotes renal fibrosis in kidney disease, but the role of HIF‐1α in AAN is unclear. Evidence shows that HIF‐1α and p21, a known inducer of cellular G2/M arrest, are closely related to each other. To investigate the role of HIF‐1α in renal fibrosis of AAN and its effects on p21 expression and PTCs G2/M arrest, mice with HIF‐1α gene knockout PTCs (PT‐HIF‐1α‐KO) were generated, and AAN was induced by AA. In vitro tests were conducted on the human PTCs line HK‐2 and primary mouse PTCs. HIF‐1α and p21 expression, fibrogenesis, and G2/M arrest of PTCs were determined. Results showed that HIF‐1α was upregulated in the kidneys of wild‐type (WT) AAN mice, accompanied by p21 upregulation, PTCs G2/M arrest and renal fibrosis, and these alterations were reversed in PT‐HIF‐1α‐KO AAN mice. Similar results were observed in HK‐2 cells and were further confirmed in primary PTCs from PT‐HIF‐1α‐KO and WT mice. Inhibiting p21 in HK‐2 cells and primary PTCs did not change the expression of HIF‐1α, but G2/M arrest and fibrogenesis were reduced. These data indicate that HIF‐1α plays a key role in renal fibrosis in AAN by inducing PTCs G2/M arrest modulated through p21. HIF‐1α may serve as a potential therapeutic target for AAN.
- Open Access
- 10 November 2019
- Published by Wiley in Cancer Medicine
- Vol. 9 (1) , 84-93
The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
Objective: KRAS mutation plays a critical role in the initiation and development of non‐small cell lung cancer (NSCLC). KRAS‐mutant patients exhibit diverse response to chemotherapy. KRAS co‐mutation subtypes and their prognosis value in advanced Chinese NSCLC patients remain largely elusive.Methods: A total of 1126 Chinese advanced NSCLC patients from Xiangya hospital were screened by capture‐based ultra‐deep sequencing for KRAS mutation between January 2015 and December 2016. Survival analyses were performed using Kaplan‐Meier analysis.Results: Among the patients screened, 84 cases were detected with KRAS mutation (7.5%). All of them were non‐squamous NSCLC and received pemetrexed plus platinum as the first‐line treatment. The most frequent KRAS co‐mutation genes were TP53 (29%), TP53/LKB1 (19%), and LKB1 (14%). Our data revealed that patients with KRAS co‐mutation had poorer prognosis in comparison with those harboring single KRAS mutation. Furthermore, patients with KPL (KRAS mutated with TP53 and LKB1) subtype, which was a novel subtype, had the shortest progression‐free survival (PFS) in all types of KRAS co‐mutation patients (P < .0001). The PFS and overall survival (OS) of patients with KRASG12D mutation were inferior than those with KRASG12C mutation or KRASG12V mutation. Patients in KRASG>T type had significantly longer survival than those in KRASG>C type or KRASG>A type.Conclusion: Our study revealed that concurrent genomic alterations can further stratify KRAS‐mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. The KPL is a novel and less responsive subtype among KRAS‐mutated NSCLC, and further investigation of effective treatment for this subtype is warranted.
- 10 November 2019
- Published by Wiley in Cancer Medicine
- Vol. 9 (1) , 84-93
Open AccessThe prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
Objective: KRAS mutation plays a critical role in the initiation and development of non‐small cell lung cancer (NSCLC). KRAS‐mutant patients exhibit diverse response to chemotherapy. KRAS co‐mutation subtypes and their prognosis value in advanced Chinese NSCLC patients remain largely elusive.Methods: A total of 1126 Chinese advanced NSCLC patients from Xiangya hospital were screened by capture‐based ultra‐deep sequencing for KRAS mutation between January 2015 and December 2016. Survival analyses were performed using Kaplan‐Meier analysis.Results: Among the patients screened, 84 cases were detected with KRAS mutation (7.5%). All of them were non‐squamous NSCLC and received pemetrexed plus platinum as the first‐line treatment. The most frequent KRAS co‐mutation genes were TP53 (29%), TP53/LKB1 (19%), and LKB1 (14%). Our data revealed that patients with KRAS co‐mutation had poorer prognosis in comparison with those harboring single KRAS mutation. Furthermore, patients with KPL (KRAS mutated with TP53 and LKB1) subtype, which was a novel subtype, had the shortest progression‐free survival (PFS) in all types of KRAS co‐mutation patients (P < .0001). The PFS and overall survival (OS) of patients with KRASG12D mutation were inferior than those with KRASG12C mutation or KRASG12V mutation. Patients in KRASG>T type had significantly longer survival than those in KRASG>C type or KRASG>A type.Conclusion: Our study revealed that concurrent genomic alterations can further stratify KRAS‐mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. The KPL is a novel and less responsive subtype among KRAS‐mutated NSCLC, and further investigation of effective treatment for this subtype is warranted.